Video 16 Oct 2024 Executive Series | Meet The Board | Professor Fiona Wood AM In the second instalment of the ‘Meet The Board’ video series, we meet Professor Fiona Wood, a world-renowned plastic and… Orthocell
Company News 08 Oct 2024 Orthocell Receives Regulatory Approval for Remplirâ„¢ in Singapore Orthocell has received regulatory approval from the Health Sciences Authority (HSA) in Singapore, allowing the Company to commence sales of… Orthocell
Company News 07 Oct 2024 Orthocell Reports Second Consecutive Quarter of Record Revenue Orthocell has today announced continued growth in sales of its market-leading medical devices, Striate+â„¢ and Remplirâ„¢. Orthocell
Video 01 Oct 2024 VIDEO | Meet The Board | CEO & MD, Paul Anderson The first episode of Orthocell’s ‘Meet the Board’ video series is now live - featuring CEO & MD, Paul Anderson. Orthocell
Video 26 Sep 2024 Launching October 2024 | Meet The Board As part of a special ‘Meet the Board’ video series launching in October 2024, we are pleased to bring you… Orthocell
Video 10 Sep 2024 Ausbiz | Interview with John Van Der Wielen Orthocell Chairman, John Van Der Wielen spoke with ausbiz host Nadine Blayney about the Company’s expansion into Canada with dental… Orthocell
Video 09 Sep 2024 Proactive | Interview with John Van Der Wielen Orthocell Chairman John Van Der Wielen speaks with Proactive’s Tylah Tully about the Company's swift transition from regulatory approval to… Orthocell
Media 06 Sep 2024 The Australian | Orthocell’s collagen-membrane dental-regeneration product Striate+ debuts in Canada Orthocell's entry to to the Canadian market with the first sales of Striate+ has been reported in The Australian in… Orthocell
Company News 06 Sep 2024 First Sales of Striate+â„¢ in New and Significant Market of Canada Orthocell has today announced global distribution partner BioHorizons has recorded a fast transition to first sales of Striate+â„¢ in the… Orthocell
Company News 05 Sep 2024 Petra Capital Research Report | September 2024 Petra Capital has released a research report valuing #Orthocell (ASX:OCC) at A$1.28 per share. The report summarises Orthocell’s revenue growth, and… Orthocell
